Last day to save 30% at the Gap, Old Navy etc and benefit the LLS
Today Sunday August 29 is the last day of the Give & Get program benefitting the Leukemia & Lymphoma Society. Click on THIS LINK and print out the coupon, you can bring it to any of the following stores in the US or Canada and get 30% off your purchase, with the LLS getting 5% of what you spend:
- Gap
- Gap Outlet
- Gap Factory Store
- The Gap Generation
- Banana Republic
- Banana Republic Factory Store
- Old Navy
Maybe you still have some back-to-school shopping to do, maybe you just want some new clothes. The Give & Get program happens, I think, twice a year—Spring and Fall. Check it out if you can, thanks!
PS--At the bottom of the coupon, there's a store finder link if you need it.
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
